Virtual Ward for Early Discharge in Patients Receiving Inpatient Care
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasmus Medical Center
About this trial
This study evaluates the feasibility of providing hospital-level care at home for eligible patients through a Virtual Ward. Patients are discharged early from the hospital and monitored remotely using digital vital sign monitoring and anamnesis questionnaires. The primary aim is to determine if at least 30% of eligible patients can be safely and successfully transferred to the Virtual Ward under current Dutch healthcare conditions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients (≥18 years old).
Currently hospitalized and eligible for early discharge according to clinical judgment.
Ability to provide written informed consent.
Access to a smartphone or tablet with internet connection.
Disqualifiers
Patients requiring continuous hospital-based monitoring or interventions that cannot be safely delivered at home.
Patients who are hemodynamically unstable or require oxygen therapy >5 liters/minute at the time of discharge.
Patients unable or unwilling to comply with home monitoring procedures.
Patients with significant cognitive impairment without adequate caregiver support.
Trial design
Design model
Single group
Treatments tested in this trial
Virtual Ward
Combination productHospital-level care at home using remote vital sign monitoring, digital anamnesis via the Digizorg app, and integration with the Electronic Medical Record (HiX), managed by Virtual Ward staff following predefined care pathways.
Treatment groups
306 Participants
are divided into 1 treatment groupGroup A: Virtual Ward armExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of Participants Successfully Transferred to the Virtual Ward After Providing Informed Consent
Successful transfer is defined as discharge from hospital to the Virtual Ward with start of home monitoring according to care pathways. Threshold for feasibility is ≥30%.
Time frame
From enrollment to transfer to Virtual Ward (during hospitalization, up to 7 days)Secondary outcomes
1
Number of Eligible Patients Invited for Participation
Eligible patients are those meeting the inclusion criteria, identified during hospitalization.
Time frame
From enrollment to invitation during hospitalization (up to 7 days)2
Number of Invited Patients Providing Informed Consent
Informed consent is obtained after providing oral and written information.
Time frame
From enrollment to signing informed consent during hospitalization (up to 7 days)3
Time from Study Inclusion to Transfer to Virtual Ward
Time is measured in days between signing informed consent and actual discharge to Virtual Ward.
Time frame
From informed consent to Virtual Ward admission (up to 7 days)4
Number of Notifications Generated During Virtual Ward Monitoring
Notifications include vital sign alerts or digital anamnesis alerts, categorized into low-exceeding or high-exceeding limits.
Time frame
From Virtual Ward admission up to 30 days after dischargeOther outcomes
1
Frailty Status Based on Clinical Frailty Scale and PRISMA-7 Questionnaire
Clinical Frailty Scale: 1 (very fit) to 9 (terminally ill); PRISMA-7 score: ≥3 indicates frailty risk.
Time frame
At enrollment (baseline)2
Patient-Reported Experience of Virtual Ward Care
Semi-structured interview assessing experiences, barriers, and facilitators, based on CFIR.
Time frame
Within 30 days after Virtual Ward discharge3
Healthcare Provider-Reported Experience of Virtual Ward Care
Semi-structured interview assessing experiences using CFIR domains and NoMAD questionnaire.
Time frame
Approximately 6-12 months after study initiationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov